Compare AbbVie Inc (ABBV) vs iShares MSCI Malaysia ETF (EWM) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

EWM, the iShares MSCI Malaysia ETF, trades at $27.24, up 1.0% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The ETF is heavily weighted in Financials (54%) and Industrials (21%), positioning it to benefit from Malaysia's data center expansion and tourism initiatives. A dividend of $0.57 is scheduled for payment on June 18, 2026.

Outlook is mixed: growth potential exists from Malaysia's economic initiatives, but bearish technicals and regional geopolitical risks from Middle East conflicts pose headwinds. Investors should weigh exposure to emerging market volatility against sector-specific opportunities in semiconductors and energy.